Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

Pfizer

Status and phase: Completed; Phase 3

Conditions: Blood Pressure, High; Hypertension

Treatments: Drug: Ramipril and hydrochlorothiazide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00355589

B5051001 (Other Identifier)

K749-06-3001

Details and patient eligibility

About

The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously diagnosed, or newly diagnosed essential hypertension. Blood pressure must be within a minimum and maximum range prior to drug treatment.

Exclusion criteria

• Inability to discontinue all prior antihypertensive medications
• Heart failure
• History of stroke, myocardial infarction, or chest pain within 3 years, or an abnormal heart rhythm
• Liver or kidney disease
• Certain drugs used to treat other conditions like an enlarged prostate gland, or arthritis
• Allergy or reactions to certain medications used to treat high blood pressure

Other protocol-defined inclusion and exclusion criteria apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind